Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

NCT04233294 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: Chidamide
DRUG: Camrelizumab
DRUG: Decitabine

Sponsor

Chinese PLA General Hospital